title: One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
abstract: OBJECTIVE
  To investigate 1-year outcomes of intravitreal aflibercept for polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  Retrospective, multicenter, consecutive case series.
  
  
  METHODS
  A total of 90 eyes of 87 patients with treatment-naïve PCV followed at 3 tertiary centers.
  
  
  METHODS
  Clinical records were reviewed and imaging studies were analyzed of eyes with PCV that underwent 3 consecutive monthly aflibercept injections followed by injections every 2 months. Additional (rescue) injections were performed for worsening.
  
  
  METHODS
  Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), and angiographic findings at 1 year.
  
  
  RESULTS
  The mean BCVA (logarithm of the minimum angle of resolution units) of the 90 eyes improved from 0.31 at baseline to 0.17 at 12 months (P < 0.001). The mean central retinal thickness decreased from 315 μm at baseline to 204 μm at 12 months (P < 0.001). At 12 months, 64 eyes (71.1%) achieved a dry macula, defined as absence of intraretinal or subretinal fluid on OCT. Of 83 eyes that underwent indocyanine green angiography at both baseline and 12 months, 46 (55.4%) showed complete and 27 (32.5%) showed partial resolution of polypoidal lesions. Eleven of 82 eyes (13.4%) showed decreased size of branching choroidal vascular networks.
  
  
  CONCLUSIONS
  Intravitreal aflibercept administered over 1 year improved both visual acuity and macular morphology in a large number of treatment-naïve eyes with PCV.
authors.affiliation: Department of Ophthalmology at Kyorin University School of Medicine, Tokyo, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Yamamoto
authors.affiliation: Department of Ophthalmology at Kyorin University School of Medicine, Tokyo, Japan. Electronic address: aokada@eye-center.org.
authors.forename: Annabelle A
authors.initials: AA
authors.lastname: Okada
authors.affiliation: Department of Ophthalmology at Fukushima Medical University, Fukushima, Japan.
authors.forename: Mariko
authors.initials: M
authors.lastname: Kano
authors.affiliation: Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Koizumi
authors.affiliation: Department of Ophthalmology at Fukushima Medical University, Fukushima, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Saito
authors.affiliation: Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Maruko
authors.affiliation: Department of Ophthalmology at Fukushima Medical University, Fukushima, Japan.
authors.forename: Tetsuju
authors.initials: T
authors.lastname: Sekiryu
authors.affiliation: Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Iida
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011127:Polyps / Q000188:drug therapy* / Q000503:physiopathology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D055213:Retinal Pigment Epithelium / Q000473:pathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D004396:Coloring Agents; D011993:Recombinant Fusion Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D007208:Indocyanine Green